Ocugen Q3 2024 cash $39M; extends runway into 1Q2026 on $65M in financings

Ocugen, Inc.

Cash and restricted cash $39.0M as of Sept 30, 2024, vs $39.5M at Dec 31, 2023.
Closed $30M debt and $35M equity financings in Q3, extending cash runway into 1Q2026.
Total operating expenses $14.4M (R&D $8.1M, G&A $6.3M) vs $16.1M in Q3 2023.
OCU400 Phase 3 liMeliGhT trial for RP on track to complete enrollment in 1H2025.
OCU410 Phase 2 recruiting; OCU410ST DSMB approved Phase 2; OCU200 IND cleared for Phase 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.